Prospective Study of Diagnostic Techniques for Breast Cancer in Brazil: Effectiveness and Accuracy
This prospective study in Brazil demonstrates that fine-needle aspiration cytology (FNAC) is a reliable, cost-effective diagnostic tool for breast lesions that, when used alongside or as an alternative to core needle biopsy, offers substantial accuracy and can improve access to care in resource-limited settings.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Breast cancer remains one of the most common and serious health challenges for women worldwide, particularly in countries where access to advanced medical care can be uneven. When a woman finds a lump or a suspicious area in her breast, doctors must determine quickly whether it is harmless or malignant. To do this, they often rely on a "triple diagnosis," combining a physical exam, imaging like mammograms, and a tissue sample taken directly from the lump. Two main methods exist for taking that sample. One uses a very thin needle to pull out loose cells for examination under a microscope, a technique known as fine-needle aspiration. The other uses a slightly larger, hollow needle to extract a tiny core of tissue, which preserves the structure of the cells and allows for a more detailed look at how they are arranged. While the tissue core method is often considered the gold standard for planning treatment, it can be more expensive and harder to obtain in public health systems. The question facing doctors in resource-limited settings is whether the simpler, cheaper cell-sampling method is accurate enough to be trusted on its own, or if it must always be followed by the more complex tissue test.
In a study conducted in Porto Alegre, Brazil, researchers set out to answer this question by comparing these two methods directly. They worked with 74 women who had breast lumps that looked suspicious for cancer. Each woman underwent both procedures: first, the thin needle was used to collect cells, and immediately afterward, the larger needle was used to take a small piece of tissue. The doctors then compared the results of both tests against the final diagnosis obtained after the women underwent surgery to remove the lumps. The goal was to see if the thin needle could reliably identify cancer without needing the tissue sample first, which would be a significant advantage in a country where cost and equipment availability can delay diagnosis.
The researchers found that the thin needle method performed remarkably well when the results were clear. When the cell sample provided a definitive answer, it correctly identified cancer in nearly 92 percent of the cases where cancer was present. It also correctly identified non-cancerous lumps in 90 percent of those cases. This means that when the test gave a positive result for cancer, it was right almost every time. However, the study also highlighted a specific limitation: the thin needle sometimes struggled to give a clear answer, returning results that were either "suspicious" or "insufficient" because not enough cells were collected. In these unclear cases, the doctors could not rely on the thin needle alone.
When the researchers looked at the bigger picture, combining the results of both the thin needle and the tissue sample, the accuracy improved significantly. Together, the two methods detected cancer in 97 percent of the cases where it was found, and they were perfect at identifying when cancer was absent. Only one woman in the entire group had a negative result on both tests but was later found to have cancer after surgery. This single case of a missed diagnosis suggests that while the methods are powerful, they are not infallible. The study also noted that the tissue sample method, while highly accurate, was more difficult to implement in this specific setting. A change in Brazilian regulations in 2006, which prohibited the reuse of the larger biopsy needles to prevent infection, increased the cost of the procedure and made it harder to secure the necessary equipment. This economic barrier meant that fewer patients could be included in the study than originally planned, and it underscored the real-world challenge of accessing the most advanced diagnostic tools in public health systems.
The findings suggest that the thin needle method is a valuable tool, particularly as a first step in the diagnostic process. It is fast, inexpensive, and safe, making it ideal for initial screening in busy clinics. The study indicates that when a doctor finds a suspicious lump, using the thin needle first can quickly confirm the presence of cancer in most cases, allowing the patient to move forward with treatment planning sooner. However, the researchers emphasize that this method should not replace the tissue sample entirely. Because the thin needle cannot always provide enough information to determine the exact type of cancer or its specific characteristics, the tissue sample remains essential for final confirmation and for planning the best course of treatment. In settings where resources are tight, the two methods work best as partners: the thin needle acts as a rapid filter to catch the majority of cases, while the tissue sample provides the detailed map needed for the most complex decisions. This approach allows doctors to balance the need for speed and cost-effectiveness with the necessity of precision, ensuring that patients receive the right care without unnecessary delays.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.